TD Cowen analyst Joseph Thome has maintained their bullish stance on QURE stock, giving a Buy rating on July 14.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Thome’s rating is based on several key factors surrounding uniQure’s AMT-130 program. The company is optimistic about the upcoming release of 3-year data, which is anticipated to demonstrate continued benefits when compared to a new external comparator. This data will be crucial as it will be the first time the Phase I/II program is analyzed using a finalized statistical analysis plan and an external control arm derived from the ENROLL-HD data set. The previous 2-year data showed a significant reduction in disease progression, and maintaining this statistical significance could potentially drive substantial upside for the stock.
Despite recent challenges faced by other gene therapy programs, uniQure remains confident in the success of AMT-130. The differences in the program’s design, such as its clinical endpoint as a primary efficacy measure and localized delivery, set it apart from others that have faced regulatory hurdles. Additionally, the safety profile has remained favorable, and the company has had productive interactions with the FDA. These factors contribute to the positive outlook and support the Buy rating given by Joseph Thome.
Thome covers the Healthcare sector, focusing on stocks such as United Therapeutics, Alkermes, and Jazz Pharmaceuticals. According to TipRanks, Thome has an average return of -2.6% and a 40.83% success rate on recommended stocks.
In another report released on July 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target.